Bayer secures global rights to PRMT5 inhibitor

27 March 2025

German drugmaker Bayer (BAYN: DE) has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive rights to develop and commercialize an early-stage precision oncology therapy targeting MTAP-deleted tumors.

The deal, announced on Wednesday, gives Bayer access to BAY 3713372, a small molecule. The company has also begun enrolling patients in a Phase I dose escalation study to assess the drug’s safety and activity in solid tumors.

Juergen Eckhardt, who leads business development and licensing at Bayer’s pharma division, said the compound offers “highly selective targeting of cancer cells while sparing healthy cells,” citing the treatment's novel mechanism of action.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK